Haratake, Naoki
Shimokawa, Mototsugu
Seto, Takashi
Yoshioka, Hiroshige
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Article History
Received: 28 January 2022
Accepted: 18 May 2022
First Online: 20 June 2022
Declarations
:
: Naoki Haratake reports personal fees from Eli Lilly Japan K.K., personal fees from AstraZeneca, personal fees from Chugai Pharmaceutical Co. Ltd, outside the submitted work. Mototsugu Shimokawa has stated that they have no conflict of interest. Takashi Seto has received grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Daiichi Sankyo, grants and personal fees from Eli Lilly Japan, grants and personal fees from MSD, grants and personal fees from Novartis Pharma, grants and personal fees from Pfizer Japan, grants and personal fees from Takeda Pharmaceutical, grants from Abbvie, grants from Kissei Pharmaceutical, grants from LOXO Oncology, grants from Merck Biopharma, personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, personal fees from Covidien Japan, personal fees from Kyowa Hakko Kirin, personal fees from Mochida Pharmaceutical, personal fees from Nippon Boehringer Ingelheim, personal fees from Ono Pharmaceutical, personal fees from Taiho Pharmaceutical, personal fees from Thermo Fisher Scientific, personal fees from Precision Medicine Asia. Hiroshige Yoshioka reports personal fees from Chugai Pharmaceutical Co. Ltd, personal fees from Eli Lilly Japan K.K., personal fees from AstraZeneca K.K, personal fees from Boehringer Ingelheim Japan Inc, personal fees from Pfizer Japan Inc., personal fees from TAIHO PHARMACEUTICAL CO., LTD., personal fees from MSD K.K., personal fees from Delta Fly Pharma, personal fees from Nippon Kayaku, personal fees from Novartis pharmaceuticals k.k, personal fees from Otsuka Pharmaceutical Co., Ltd., outside the submitted work. Nobuyuki Yamamoto reports personal fees from AstraZeneca, personal fees from MSD K.K., personal fees from ONO PHARMACEUTICAL CO., LTD., personal fees from Thermo Fisher Scientific, personal fees from DAIICHI SANKYO CO., grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD., personal fees from Takeda Pharmaceutical CO., LTD., grants and personal fees from Chugai Pharmaceutical CO., LTD., personal fees from Eli Lilly Japan K.K., grants and personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from Pfizer Inc., personal fees from Bristol-Myers Squibb, personal fees from NIPPON KAYAKU, personal fees from GlaxoSmithKline K.K., personal fees from Sanofi K.K., personal fees from Hisamitsu Pharmaceutical Co.Inc, personal fees from Merk biopharma, grants from Tosoh Life Science Research Laboratory, outside the submitted work. Kazuhiko Nakagawa reports grants and personal fees from AstraZeneca K.K., grants and personal fees from Astellas Pharma Inc., grants and personal fees from MSD K.K., grants, personal fees and other from Ono Pharmaceutical Co., Ltd., grants and personal fees from Nippon Boehringer Ingelheim Co., Ltd., grants and personal fees from Novartis Pharma K.K., grants, personal fees and other from Pfizer Japan Inc., grants and personal fees from Bristol Myers Squibb Company, grants, personal fees and other from Eli Lilly Japan K.K., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., grants and personal fees from Merck Serono Co., Ltd./ Merck Biopharma Co., Ltd., during the conduct of the study; personal fees from Clinical Trial Co., Ltd., personal fees from MEDICUS SHUPPAN, Publishers Co., Ltd., personal fees from Care Net, Inc, personal fees from Reno. Medical K.K., personal fees and other from KYORIN Pharmaceutical Co., Ltd., personal fees from Medical Review Co., Ltd., personal fees from Roche Diagnostics K.K., personal fees from Bayer Yakuhin, Ltd, personal fees from Medical Mobile Communications co., Ltd, personal fees from 3H Clinical Trial Inc., personal fees from Nichi-Iko Pharmaceutical Co., Ltd., grants, personal fees and other from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from SymBio Pharmaceuticals Limited., personal fees from NANZANDO Co., Ltd., personal fees from YODOSHA CO., LTD., personal fees from Nikkei Business Publications, Inc, personal fees from Thermo Fisher Scientific K.K., personal fees from YOMIURI TELECASTING CORPORATION., personal fees from Nippon Kayaku Co., Ltd., grants and personal fees from AbbVie Inc, grants from inVentiv Health Japan, grants from ICON Japan K.K., grants from GRITSONE ONCOLOGY.INC, grants from PAREXEL International Corp., grants from Kissei Pharmaceutical Co., Ltd., grants from EPS Corporation., grants from Syneos Health., grants from Pfizer R&D Japan G.K., grants from A2 Healthcare Corp., grants from Quintiles Inc. / IQVIA Services JAPAN K.K., grants from EP-CRSU CO., LTD., grants from Linical Co., Ltd., grants from Eisai Co., Ltd., grants from CMIC Shift Zero K.K., grants from Kyowa Hakko Kirin Co., Ltd, grants from Bayer Yakuhin, Ltd, grants from EPS International Co., Ltd,., grants from Otsuka Pharmaceutical Co., Ltd., outside the submitted work. Tetsuya Mitsudomi has received grants and personal fees from AstraZeneca, grants and personal fees from Eli-Lilly, during the conduct of the study; grants and personal fees from Boehringer-Ingeleheim, grants and personal fees from Chugai, grants and personal fees from Ono, personal fees from BMS, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Taiho, personal fees from Amgen, personal fees from Novartis, personal fees from Merck Biopharma, personal fees from Takeda, personal fees from Ddaiichi-Sankyo, outside the submitted work.
: All patients provided their written informed consent before study registration, and the study protocol was approved by the institutional ethics committee of each participating institution. The study was undertaken in accordance with the Declaration of Helsinki. All authors gave their final approval for the version to be published.